# Radiopharmaceutical Chemistry and Applications **Type:** Topics **Canonical URL:** https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the development, synthesis, and application of radiopharmaceuticals for PET and SPECT imaging, targeted therapy, radioimmunotherapy, and alpha particle therapy in cancer treatment. It covers topics such as coordinating radiometals, chelators, dosimetry, and the use of specific radionuclides for therapeutic purposes. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t11395 | | Works | 141 | ## Topic papers all Showing 15 of 141. - [Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ](https://scholariq.org/papers/screening-gt-recombinant-clones-by-hybridization-to-single-plaques-in-situ/) - [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/) - [AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer](https://scholariq.org/papers/ar-v7-and-resistance-to-enzalutamide-and-abiraterone-in-prostate-cancer/) - [Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study](https://scholariq.org/papers/prostate-specific-membrane-antigen-pet-ct-in-patients-with-high-risk-prostate/) - [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/) - [Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.](https://scholariq.org/papers/brain-natriuretic-peptide-as-a-novel-cardiac-hormone-in-humans-evidence-for-an/) - [Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial](https://scholariq.org/papers/radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate/) - [\[177Lu\]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study](https://scholariq.org/papers/177lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration/) - [Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer](https://scholariq.org/papers/outcomes-of-observation-vs-stereotactic-ablative-radiation-for-oligometastatic/) - [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term/) - [\[177Lu\]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration/) - [Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis](https://scholariq.org/papers/sensitivity-specificity-and-predictors-of-positive-68-ga-prostate-specific/) - [Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis](https://scholariq.org/papers/gallium-68-prostate-specific-membrane-antigen-positron-emission-tomography-in/) - [Radiopharmaceutical therapy in cancer: clinical advances and challenges](https://scholariq.org/papers/radiopharmaceutical-therapy-in-cancer-clinical-advances-and-challenges/) - [Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/abiraterone-acetate-plus-prednisone-in-patients-with-newly-diagnosed-high-risk/) ## Topic primary papers Showing 15 of 29. - [Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.](https://scholariq.org/papers/brain-natriuretic-peptide-as-a-novel-cardiac-hormone-in-humans-evidence-for-an/) - [Radiopharmaceutical therapy in cancer: clinical advances and challenges](https://scholariq.org/papers/radiopharmaceutical-therapy-in-cancer-clinical-advances-and-challenges/) - [Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer](https://scholariq.org/papers/results-of-a-randomized-phase-iii-trial-to-evaluate-the-efficacy-of-strontium-89/) - [Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/) - [Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study](https://scholariq.org/papers/bone-targeted-radium-223-in-symptomatic-hormone-refractory-prostate-cancer-a/) - [Radiotheranostics in oncology: current challenges and emerging opportunities](https://scholariq.org/papers/radiotheranostics-in-oncology-current-challenges-and-emerging-opportunities/) - [Technetium-99m-1,2-bis\[bis(2-ethoxyethyl) phosphino\]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.](https://scholariq.org/papers/technetium-99m-1-2-bis-bis-2-ethoxyethyl-phosphino-ethane-human-biodistribution/) - [A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone](https://scholariq.org/papers/a-prospective-randomised-double-blind-crossover-study-to-examine-the-efficacy-of/) - [Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate](https://scholariq.org/papers/sr-89-therapy-strontium-kinetics-in-disseminated-carcinoma-of-the-prostate/) - [\[18F\]FDG Uptake and PCNA, Glut-1, and Hexokinase-II Expressions in Cancers and Inflammatory Lesions of the Lung](https://scholariq.org/papers/18f-fdg-uptake-and-pcna-glut-1-and-hexokinase-ii-expressions-in-cancers-and/) - [Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results.](https://scholariq.org/papers/evaluation-of-111in-dtpa-folate-as-a-receptor-targeted-diagnostic-agent-for/) - [A sensitive radioimmunoassay for the antiviral agent BW248U \[9-(2-hydroxyethoxymethyl)guanine\]](https://scholariq.org/papers/a-sensitive-radioimmunoassay-for-the-antiviral-agent-bw248u-9-2/) - [Cyclotron production of 99mTc: Experimental measurement of the 100Mo(p,x)99Mo, 99mTc and 99gTc excitation functions from 8 to 18 MeV](https://scholariq.org/papers/cyclotron-production-of-99mtc-experimental-measurement-of-the-100mo-p-x-99mo/) - [Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas](https://scholariq.org/papers/zirconium-89-labeled-panitumumab-a-potential-immuno-pet-probe-for-her1/) - [Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours](https://scholariq.org/papers/radiation-precautions-for-inpatient-and-outpatient-177lu-dotatate-peptide/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.